Spark Therapeutics, Inc.
|
|
- Jeffery Stewart
- 6 years ago
- Views:
Transcription
1 Spark Therapeutics, Inc. Corporate Overview November
2 Forward looking statements This presentation contains "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's product candidates, including LUXTURNA TM (voretigene neparvovec), SPK 7001, SPK 9001 and SPK The words anticipate, believe, expect, intend, may, plan, predict, will, would, could, should, continue and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. Any forward looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward looking statements. These risks and uncertainties include, but are not limited to, the risk that: (i) our BLA or MAA for LUXTURNA may not be approved by the FDA or EMA respectively; (ii) the data from our Phase 3 clinical trial of LUXTURNA may not support labeling for all biallelic RPE65 mutations other than Leber congenital amaurosis (LCA); (iii) the improvements in functional vision demonstrated by LUXTURNA in our clinical trials may not be sustained over extended periods of time; (iv) interim data from our SPK 7001 Phase 1/2 clinical trial, including data to be generated from our recently expanded cohort, may not support further development of this product candidate; (v) our early preliminary clinical results for our product candidate, SPK 8011, for hemophilia A may not be sustained or sufficient to support further development; (vi) we may be unsuccessful in achieving higher factor VIII activity levels through dose escalation in our phase 1/2 clinical trial of SPK 8011; (vii) our lead SPK FIX product candidate, SPK 9001, may not produce sufficient data in our Phase 1/2 clinical trial to warrant further development; (viii) our early preliminary data in our phase 1/2 clinical trial of SPK 8011 have yet to be audited and therefore are subject to confirmation in connection with a clinical trial audit; and (ix) any one or more of our product candidates in preclinical or clinical development will not successfully be developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in our Annual Report on Form 10 K, our Quarterly Reports on Form 10 Q and other filings we make with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Spark undertakes no duty to update this information unless required by law. LUXTURNA TM is the trademark of Spark Therapeutics, Inc. 2
3 Spark is a fully integrated gene therapy platform company seeking to challenge the inevitability of genetic disease Validated gene therapy platform: human proof of concept data in 3 programs in the retina (LUXTURNA TM [voretigene neparvovec]) and hemophilia (SPK 8011 and SPK 9001) Investigational LUXTURNA represents the first marketing application for a gene therapy for a genetic disease in the U.S. with FDA action expected in January 2018; MAA validated by EMA Unanimous October 2017 FDA Advisory Committee vote (16 0) in favor of approval Investigational SPK 8011 for hemophilia A preliminary Phase 1/2 data provide proof of concept: 5 participants infused to date at three doses: 5x10 11 vg/kg (n=2); 1x10 12 vg/kg (n=2); and 2x10 12 vg/kg (n=1) Factor VIII (FVIII) levels of 14% and 11% seen in first 2 participants at initial dose, as of August 1 No spontaneous bleeds or serious adverse events (SAEs) reported as of August 1, including no FVIII inhibitors and no thrombotic events Investigational SPK 9001 for hemophilia B preliminary Phase 1/2 data: predictable results leading to a reduction of 96% in ABR 1 and 99% in AIR 2 as of 6/5/17 with cumulative follow up of 9.6 patient years; no SAEs to date Investigational SPK 7001 Phase 1/2 trial in choroideremia ongoing $575 million in cash, cash equivalents and marketable securities at September 30 1 Annualized bleeding rate; 2 Annualized infusion rate The safety and efficacy of investigational LUXTURNA (voretigene neparvovec) have not been demonstrated. 3
4 Investigational LUXTURNA (voretigene neparvovec) under regulatory review and positioned potentially to be the first gene therapy for a genetic disease in the U.S. 4
5 LUXTURNA under FDA and EMA regulatory review potential to be first approved gene therapy for a genetic disease in U.S. Proposed US Indication: LUXTURNA for the treatment of patients with vision loss due to confirmed biallelic RPE65 mutation associated retinal dystrophy FDA Ad Com unanimously (16 0) recommended approval of LUXTURNA FDA pre approval inspection completed without critical observations PDUFA date of Jan. 12, 2018 MAA validated by European Medicines Agency Gain in functional vision based on MLMT 1 in 93% (27/29) of Phase 3 participants at 1 year with 72% achieving maximum improvement (to 1 lux) no product related SAEs observed 3 year data (n=20) and 4 year data (n=4) from Phase 3 add evidence to durability of effect; no statistically significant signs of a waning of therapeutic effect 1 Multi luminance mobility test. The safety and efficacy of investigational LUXTURNA (voretigene neparvovec) have not been demonstrated. 5
6 Spark is taking an innovative and patient centric approach to launch preparation for investigational LUXTURNA PATIENT IDENTIFICATION CONVERSION PATIENT EXPERIENCE MARKET ACCESS Build a system to continually identify appropriate patients Prepare the market to receive LUXTURNA by developing and communicating the story of gene therapy and IRD therapy Establish a seamless system to support appropriate patient care across the patient journey Obtain/establish quality coverage and appropriate reimbursement for LUXTURNA across all channels IDYourIRD has been well received Ongoing education on IRD, and importance of genetic testing and onetime gene therapies Treatment Centers identified to support appropriate patient care, and will be trained postapproval Tested multiple approaches to valuing long term functional improvements to vision Continue to ID and process patient kits Promotional messaging platform & tools are being finalized for approval & launch Patient Services system & processes are being developed for launch; supply and distribution plan in late stage development Standard and innovative approaches to access being explored; development of patient support programs in progress The safety and efficacy of investigational LUXTURNA (voretigene neparvovec) have not been demonstrated. 6
7 Natural history of biallelic RPE65 mutations characterized by early, profound and continuous visual decline Unaffected vision Impaired VA and visual field (VF) Impaired visual acuity (VA) Impaired VA, VF and light sensitivity 7 Private and Confidential
8 Investigational LUXTURNA (voretigene neparvovec) Phase 3 trial participant: Functional vision significantly impaired at baseline CH 41: baseline visit at 4 lux (Fail) Source: Spark Phase 3 trial source data The safety and efficacy of investigational LUXTURNA (voretigene neparvovec) have not been demonstrated. 8
9 Investigational LUXTURNA (voretigene neparvovec) Phase 3 trial: Improved functional vision, as measured by primary endpoint*, through a one time administration CH 41: 1 year visit after LUXTURNA administration at 4 lux (Pass) *Multi luminance mobility test (MLMT) Source: Spark Phase 3 trial source data Note: The videos of CH 41 are representative of the mean MLMT improvement demonstrated in the intervention group in the Phase 3 trial. The safety and efficacy of investigational LUXTURNA (voretigene neparvovec) have not been demonstrated. 9
10 Investigational LUXTURNA (voretigene neparvovec) Phase 3 clinical data: Results from a varied set of endpoints Secondary endpoint: Full field light sensitivity threshold White light [ log10(cd.s/m 2 )] Mean FST: white light, averaged over both eyes (mitt) BL D30 D90 D180 Y1 Y2 BL D30 D90 D180 Y1 p <0.001 at one year Abbreviation: BL = baseline, FST = full field light sensitivity threshold mitt population for 301 study. Intervals are +/ one standard error Mean MLMT: lux score/level, bilateral (mitt) 1 lux 4 lux 10 lux 50 lux 125 lux 250 lux 400 lux Abbreviation: BL = baseline, MLMT = multi luminance mobility test mitt population for 301 study. Intervals are +/ one standard error Gain in functional vision based on MLMT in 93% (27/29) of Phase 3 participants at 1 year with 72% achieving maximum improvement (to 1 lux) No product related SAEs or deleterious immune responses 1 >150 fold average improvement in light sensitivity (FST) BL D30 D90 D180 Y1 Y2 BL D30 D90 D180 Y1 p=0.004 at one year Another secondary endpoint, visual acuity, did not reach statistical significance; 9 letter improvement (p=0.17) Visual Field (VF) improved on two measures with a near doubling in Goldmann VF Lux score Primary endpoint Goldmann III4e (sum total degrees) Additional protocolspecified endpoint Mean Goldmann Visual Field III4e: both eyes (mitt) Abbreviation: BL = baseline, mitt population for 301 study. Intervals are +/ one standard error BL D30 D90 D180 Y1 Y2 BL D30 D90 D180 Y1 p=0.006 at one year Source: Spark data presented at The Retina Society, October 2015; Spark data on file (unpublished). (1) One SAE (serious adverse event) in one eye deemed related to surgical procedure The safety and efficacy of investigational LUXTURNA (voretigene neparvovec) have not been demonstrated. 10
11 Data support potential value of a one time administration of investigational LUXTURNA (voretigene neparvovec) to deliver longer term results Health economic (HEOR) modeling is an important approach to assessing value HEOR modeling should include direct costs, quality of life, indirect costs and durability of effect Indirect costs have significant economic consequences 70% of working age Americans who are blind are unemployed Substantial caregiver and societal costs, such as lost wages and increased educational costs Value conclusions from ongoing HEOR modeling corroborated independently by society (e.g., long term disability, court cases) 3 year data (n=20) and 4 year data (n=4) from Phase 3 add evidence to durability of effect; no statistically significant signs of a waning of therapeutic effect Mean MLMT: lux score/level, bilateral (mitt) 301 and 302 study lux score/level, injected eye 102 cohort 1 lux 6 4 lux 10 lux 50 lux 125 lux 250 lux 400 lux Source: Spark data presented at The Retina Society, October 2015; The Lancet; Spark data on file (unpublished). *Spark data on file. Lux score Abbreviation: BL = baseline, MLMT = multi luminance mobility test mitt population for 301 study. Intervals are +/ one standard error BL D30 D90 D180 Y1 Y2 Y3 BL D30 D90 D180 Y Original intervention (n = 20) 301 Control/intervention (n = 9) 102 (n = 8) Mean FST: white light, averaged over both eyes (mitt) 301 and 302 study white light, injected eye 102 cohort White light [ log10(cd.s/m 2 )] BL D30 D90 D180 Y1 Y2 Y3 Y4 BL D30 D90 D180 Y1 Abbreviation: BL = baseline, FST = full field light sensitivity threshold, mitt population for 301 study. Intervals are +/ one standard error The safety and efficacy of investigational LUXTURNA (voretigene neparvovec) have not been demonstrated. 301 Original intervention (n = 20) 301 Control/intervention (n = 9) 102 (n = 8) Y4
12 Investigational LUXTURNA (voretigene neparvovec) Phase 3 safety overview years 1 and 2: No product related SAEs Most common treatment emergent ocular adverse events Number of participants (n=29) Increased intraocular pressure 5 Cataracts 4 Retinal tear 3 Retinal deposit* 3 Macular hole 2 Transient and mild eye inflammation 2 Eye pain 2 Eye pruritus 2 Procedure related serious adverse event Number of participants (n=29) Loss of foveal function (visual acuity) right eye 1 *Asymptomatic, self limiting, subretinal precipitates Sources: Russell et al. Abstract presented at: Retina Society 48th Annual Scientific Meeting; October 7 11, 2015; Paris, France. Data on file. Spark Therapeutics, Inc. The safety and efficacy of investigational LUXTURNA (voretigene neparvovec) have not been demonstrated. 12
13 Demonstrated leadership in applying gene therapy technology to hemophilia 13
14 Spark objectives for developing an optimized gene therapy for hemophilia Safety Low, effective dose to reduce risk of SAEs Restore hemostasis by leveraging innate biology rather than bypassing normal physiological pathways Factor activity levels >12% at all times reduces risk of bleeds and need for chronic infusions No thrombosis or inhibitors Predictable and consistent results Participants within an acceptable factor activity range >12% and below levels that could introduce new safety risks Sustained factor expression Without the troughs that characterize regular infusions of protein therapeutics Reduce treatment burden and improve QoL Note: Black lines are medians; shaded areas interquartile ranges. Source: Adapted from den Uijl IE et. al. Haemophilia 2011; 17(6):
15 Spark is two for two in achieving proof of concept in hemophilia gene therapy Safety SPK 9001 for hemophilia B No SAEs reported, including no FIX inhibitors and no thrombotic events as of June 5, 2017 SPK 8011 for hemophilia A No SAEs reported, including no FVIII inhibitors and no thrombotic events as of August 1, 2017 Evidence of predictability and consistency Predictability of results: No confirmed bleeds observed in initial 10 participants in 9.6 cumulative years of follow up, as of June 5 11/11 participants with >12% FIX activity Consistent FIX activity levels achieved All participants well within an acceptable range Initial 2 treated participants achieved 14% and 11% FVIII activity, as of August 1, at dose of 5x10 11 vg/kg No spontaneous bleeds reported Evidence of sustainability Sustained FIX expression with 1 participant out 18 months post infusion and 4 others out over one year as of June 5 First participant out over 5 months, second participant out ~3 months post infusion as of August 1 Data as of June 5 th, 2017 (latest update) for SPK 9001 and August 1 st, 2017 for SPK Note: Two SPK 9001 trial participants experienced asymptomatic, transient elevation in liver enzymes, or decline in FIX activity, potentially indicative of an immune response to the Spark100 capsid. Both received a tapering course of corticosteroids (now completed) after which their ALTs returned to baseline, while factor IX activity levels have remained stable. As of June 5th, neither participant had experienced a bleed nor taken factor concentrates. Source: SPK 8011 preliminary initial Phase 1/2 data per investigator reporting; and therefore are subject to confirmation in connection with a clinical trial audit. Factor activity refers to FVIII:C values from local labs. 15
16 Preliminary SPK 9001 Phase 1/2 data in hemophilia B: Consistent and sustained FIX activity within target range in initial 10 participants 12 weeks 1 year 90% FIX:C Activity (% of normal) 75% 60% 45% 30% 15% 30% 79%* 25% 18% 16%* 44% 43% 38% 24% 33% 100 IU/kg EHL-rFIX, BeneFIX, or MonoNine 0% Months post vector administration Source: Spark data as of June 5, 2017; Participant 1 80 week data as of June 22, FIX:C Activity = circulating factor IX activity level EHL rfix Extended half life recombinant factor IX *These two participants experienced asymptomatic, transient elevation in liver enzymes, or decline in FIX activity, potentially indicative of an immune response to the Spark100 capsid. Both received a tapering course of corticosteroids (now completed) after which their ALTs returned to baseline, while factor IX activity levels remained stable. As of June 5 th, neither participant had experienced a bleed nor taken factor concentrates. 16
17 Preliminary SPK 9001 Phase 1/2 data in hemophilia B: Predictable results for initial 10 participants in FIX activity target range Annualized Bleeding Rate First ten participants free of confirmed bleeds Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 Participant 6 Participant 7 Participant 8 Participant 9 Participant 10 Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 Participant 6 Participant 7 Participant 8 Participant 9 Participant 10 Prior 1 year 0 0 4* Pre-trial bleed Suspected bleed After vector infusion (22-80 weeks) Nine of the ten initial participants have not taken factor IX concentrates to prevent or control bleeding events since vector administration FIX infusions: prior 1 yr. vs. after vector administration Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 Participant 6 Participant 7 Participant 8 Participant 9 Participant 10 Prior 1 year Prophylaxis infusion On-demand infusion Infusion for suspected bleed * Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 Participant 6 Participant 7 Participant 8 Participant 9 Participant 10 After vector infusion (22-80 weeks) Note: SPK 9001 data as of last visit prior to June 5, 2017; most recent update. SPK 8011 data as of August 1, *SPK 9001 Participant 3 self infused factor concentrates for suspected ankle bleed on Day 2 after vector infusion and self administered precautionary infusions another nine times between Dec. 2, 2016 and Jan 2, 2017 for persistent knee pain. Participant has not used factor concentrates since Jan. 2. **SPK 8011 Participant 1 infused factor following an emergency dental extraction in Week 6 post infusion, while Participant 3 infused factor subsequent to a traumatic ankle injury on Day 2 post infusion. No documented use for either participant of additional factor concentrates through 8/1. 17
18 Preliminary SPK 8011 Phase 1/2 data in hemophilia A as of August 1: First 2 participants stable with double digit FVIII activity; doseescalation ongoing 15% 14% FVIII:C Activity (% of normal) 12% 9% 6% 3% 8% Two additional participants have been dosed since last update on August 1. Participant 4 received same dose as participant 3 (1x10 12 vg/kg), with participant 5 receiving the next dose of 2x10 12 vg/kg. Next data update to be provided at ASH. 11% 0% Days post vector administration Note: Data as of 8/1/17; Subject 1 infused factor following an emergency dental extraction in Week 6 post infusion. Reading shortly thereafter recorded 19% activity level; excluded from this graph due to factor infusion proximity. Subject 3 infused factor subsequent to a traumatic ankle injury on Day 2 post infusion; Day 7 read deemed not to be impacted by any residual Factor from infusion. Factor activity refers to FVIII:C values from local labs. 18 Private and Confidential
19 Fully integrated AAV gene therapy platform 19
20 Spark has programs across 3 target tissues, with 4 candidates in clinical trials and 3 with human proof of concept Preclinical Phase 1/2 Phase 3 Registration INHERITED RETINAL DISEASES (IRDs) LUXTURNA (voretigene neparvovec): IRD due to biallelic RPE65 mutations* SPK 7001: Choroideremia LHON 1 Undisclosed LIVER MEDIATED DISEASES SPK 8011: Hemophilia A SPK 9001: Hemophilia B Undisclosed (Genethon) NEURODEGENERATIVE DISEASES CLN2 disease 2 Huntington s disease Cutting edge vector design State of the art manufacturing expertise Innovative scientific and regulatory strategies Strong commitment to improve patient care 1 Leber hereditary optic neuropathy; 2 A form of Batten Disease. *BLA filing under review in the US; MAA validated by EMA. 20
21 Interim data from ongoing SPK 7001 P1/2 trial in CHM: No productrelated SAEs with 15 participants dosed; follow up ongoing Choroideremia is slow progressing, affecting ~12,500 males in US / EU5 To study safety, initiated 2 year Phase 1/2 trial in 10 participants with later stage disease SPK 7001 administration resulted in no product related SAEs At interim analysis 1, 4/10 later stage participants showing non statistically significant indications of efficacy on 1 or more endpoints Non significance of results may be due to duration of follow up and later stage of disease in this cohort Completed enrollment in additional cohort of 5 participants at an earlier stage of disease hrep1: crep1 mrna Ratio of REP1 levels in preclinical model Control Goal = x 10" µg/eye Source: Spark unpublished preclinical data. Next steps: Conduct analysis at 2 year timepoint on first 10 participants 1 At time of interim analysis, had 1 year of follow up on 5 participants, 18 months of follow up on 4 and the targeted 2 year data for 1 21
22 Spark s AAV manufacturing platform is the product of years of experience and optimization Manufacturing processes in use Purpose built, multi suite, in house cgmp facility Adherent cell culture (HEK293 mammalian cell line), transient transfection process Implemented a scalable all column downstream purification process Technology capable of being scaled linearly 50+ sub lots manufactured to date at Spark 24 assays developed for, and being used in, production of LUXTURNA Sufficient scale for IRDs (including LUXTURNA TM ) and Hemophilia B Processes currently being implemented Proof of concept achieved in a fully scalable, serum free suspension cell culture system utilizing our current HEK293 cell line Natural AAV hosts produce higher specificactivity vectors vs. non mammalian cells Reduces risk of potentially immunogenic residual impurities and pathogenicity and requirement for helper viruses Maintains product continuity Leverages current quality systems Ongoing scale up and implementation of new upstream process Designed to support anticipated requirements for potential Hemophilia A and other future potential gene therapy products 22
23 Recent and upcoming clinical and regulatory catalysts Preclinical Phase 1/2 Phase 3 INHERITED RETINAL DISEASES (IRDs) Registration LUXTURNA (voretigene neparvovec): IRD due to biallelic RPE65 mutations* SPK 7001: Choroideremia LIVER MEDIATED DISEASES SPK 8011: Hemophilia A SPK 9001: Hemophilia B IRD catalysts May 2017: Interim SPK 7001 readout July 2017: LUXTURNA BLA acceptance and filing August 2017: Completed FDA PAI August 2017: LUXTURNA MAA validation October 2017: Unanimous Ad Com vote (16 0) in favor of LUXTURNA approval January 2018: LUXTURNA PDUFA date Liver mediated disease catalysts July 2017: SPK 9001 update on P1/2 data in hemophilia B August 2017: Initial topline readout of P1/2 dose escalation study of SPK 8011 in hemophilia A ASH 2017: Presentation of interim data from P1/2 study of SPK 8011 in hemophilia A *BLA filing under review in the US; MAA validated by EMA. 23
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. Corporate Overview August 2018 1 Forward looking statements This presentation contains "forward looking statements" within the meaning of the Private Securities Litigation Reform
More informationTogether, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days
Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationCorporate Overview. January Investor communication only: Not for use in promotion
Corporate Overview January 2019 1 Forward looking statements This presentation contains "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including
More informationuniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients
More informationClinical Development and Regulatory Review for LUXTURNA TM (voretigene neparvovec-rzyl), First Gene Therapy Approved for a Genetic Disease in the US
Clinical Development and Regulatory Review for LUXTURNA TM (voretigene neparvovec-rzyl), First Gene Therapy Approved for a Genetic Disease in the US LUXTURNA is an adeno-associated virus vector based gene
More informationCorporate Presentation
Corporate Presentation Forward-looking statements This presentation includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial
More informationvision is our mission NASDAQ: OPHT October 2018
vision is our mission NASDAQ: OPHT October 2018 Forward-looking Statements Any statements in this presentation about Ophthotech s future expectations, plans and prospects constitute forwardlooking statements
More informationPlanned Acquisition of Nightstar Therapeutics
Planned Acquisition of Nightstar Therapeutics Gene Therapy Candidates for Inherited Retinal Disorders March 4, 2019 1 1 Forward looking statements This presentation contains forward-looking statements,
More informationSpark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More information35 th Annual J.P. Morgan Healthcare Conference. Jean-Jacques Bienaimé Chairman and Chief Executive Officer BioMarin Pharmaceutical Inc.
35 th Annual J.P. Morgan Healthcare Conference Jean-Jacques Bienaimé Chairman and Chief Executive Officer BioMarin Pharmaceutical Inc. January 9, 2017 Safe Harbor Statement This non-confidential presentation
More informationCATALYST BIOSCIENCES. Corporate Overview. 12 February 2019
CATALYST BIOSCIENCES Corporate Overview 12 February 2019 Forward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements,
More informationCATALYST BIOSCIENCES. Corporate Overview. 9 April 2019
1 CATALYST BIOSCIENCES Corporate Overview 9 April 2019 Forward looking statements This presentation includes forward-looking statements that involve substantial risks and uncertainties. All statements,
More informationALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES
ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES Novel Development Programs for Potential Treatments of Serious Ocular
More informationGaining Momentum in Gene Therapy
Gaining Momentum in Gene Therapy Corporate Deck March 6, 2019 Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial results that
More informationInherited Retinal Diseases research at Moorfields
Recruiting Research Studies Inherited Retinal Diseases research at Moorfields Moorfields Eye Hospital wants to improve access to clinical research studies for all patients within the NHS and provide the
More informationRetinal Degenerations
Treatments and Clinical Trials for Retinal Degenerations Jacque Duncan, M.D. UCSF Kearn Family Center for the Study of Retinal Degeneration December 4, 2015 Financial Disclosures Grant Support Consultant/Scientific
More informationVisionary Science for Life Changing Cures OIS 2017
Visionary Science for Life Changing Cures OIS 2017 1 Forward Looking Statements Today s presentation includes forward-looking statements intended to qualify for the Safe Harbor from liability established
More informationWhere are we with gene therapy?
Where are we with gene therapy? Session 9: Gene Based Therapies Professor Alan Boyd PFPM 7 th February 2018 Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians, UK Topics to be covered Gene
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationUpdates in Hemophilia: Making Headway in the Multidisciplinary Setting
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationGaining Momentum in Gene Therapy
Gaining Momentum in Gene Therapy Corporate Presentation November 2018 Forward-looking Statements Statements contained in this document regarding matters, events, statistics, or clinical or financial results
More informationClinical experience with Raxone (idebenone) in the treatment of patients with Leber s Hereditary Optic Neuropathy (LHON)
Clinical experience with Raxone (idebenone) in the treatment of patients with Leber s Hereditary Optic Neuropathy (LHON) Günther Metz, Santhera Pharmaceuticals Disclaimer 2 This presentation is not and
More informationIntroduction KEY POLICY IMPLICATIONS SUMMARY A LOOK AT EMICIZUMAB FOR FOR HEMOPHILIA A WITH A INHIBITORS WITH INHIBITORS HEMOPHILIA A
A LOOK AT EMICIZUMAB FOR FOR HEMOPHILIA A WITH A INHIBITORS WITH INHIBITORS APRIL 2018 Introduction HEMOPHILIA A Hemophilia A is an inherited condition that results in a deficiency in the factor VIII blood
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationDecember 8 December 14, 2017
December 8 December 14, 2017 Page Genentech s HEMLIBRA (emicizumab-kxwh) Continued to Substantially 2 Reduce Bleeds in People with Hemophilia A with Inhibitors BioMarin Highlights New Results for Gene
More informationGene Therapy for Hemophilia A: Are we really getting better?
Gene Therapy for Hemophilia A: Are we really getting better? XXIV Congresso Nazionale SISET Novembre 10, 2016 Abano Terme Valder R. Arruda The Children s Hospital of Philadelphia University of Pennsylvania
More informationAdvancing Manufacturing for Advanced Therapies
Advancing Manufacturing for Advanced Therapies Peter Marks, MD, PhD Center For Biologics Evaluation and Research, FDA CASSS Cell & Gene Therapy Symposium July 10, 2018 Overview Cell and gene therapy products
More informationDISCLAIMER: This presentation was delivered at the Nashville Vision Seminar on February 10, This presentation is for informational purposes
DISCLAIMER: This presentation was delivered at the Nashville Vision Seminar on February 10, 2018. This presentation is for informational purposes only and is copyrighted by the Foundation Fighting Blindness.
More informationOpexa Therapeutics, Inc.
Opexa Therapeutics, Inc. November 2011 Neil Warma President & CEO Forward-Looking Statements This presentation contains forward-looking statements which are made pursuant to the safe harbor provisions
More informationAbdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018
Personalized hemophilia treatment Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018 Evolution of Hemophilia
More informationCorporate Presentation OCTOBER 2018
Corporate Presentation OCTOBER 2018 This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationTotal urinary GAGs declined by 51%, dermatan sulfate by 32%, and heparan sulfate by 61% in Cohort 2 at 16 weeks
September 5, 2018 Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationpsivida Corp PSDV June 2016
psivida Corp PSDV June 2016 Safe Harbor Statement Safe Harbor Statement SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking,
More informationStealth BioTherapeutics Mission:
The following is a summary of a live presentation offered through joint collaboration with UMDF, MitoAction and the Foundation for Mitochondrial Medicine to the mitochondrial disease patient and family
More informationDisclosure. Hemophilia: The Royal Treatment. Objectives. Background. History of Hemophilia. Epidemiology 1/4/2018
Disclosure Hemophilia: The Royal Treatment Nikki Heeren, PharmD PGY1 Resident Avera McKennan Hospital I have had no financial relationship over the past 12 months with any commercial sponsor with a vested
More informationCorporate Presentation JANUARY 2019
Corporate Presentation JANUARY 2019 Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements,
More informationReport from the CAT expert meeting
16 March 2018 EMA/CAT/60852/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Report from the CAT expert meeting Scientific and regulatory considerations for adeno-associated
More informationRegulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018
Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018 Rachel Witten, M.D. Medical Officer Office of Tissues and Advanced Therapies Center for
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Safe Harbor Statement This presentation (the Presentation ) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationEMERGING THERAPIES FOR BLINDING EYE DISEASES
EMERGING THERAPIES FOR BLINDING EYE DISEASES Mary Sunderland, PhD, MSc Director of Research & Education Foundation Fighting Blindness msunderland@ffb.ca 1.800.461.3331 ext. 238 MISSION Lead the fight against
More informationA Novel Approach to Ocular Gene Therapy: Evaluation of Suprachoroidally Administered Non-Viral DNA Nanoparticles in Rabbits
A Novel Approach to Ocular Gene Therapy: Evaluation of Suprachoroidally Administered Non-Viral DNA Nanoparticles in Rabbits Szilárd Kiss, MD Division Chief, Retina Service Director of Clinical Research
More informationDUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016 FORWARD LOOKING STATEMENTS This presentation,
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationPrior Authorization Criteria Hemophilia/Blood Factor Products
Prior Authorization Criteria Hemophilia/Blood Factor Products All requests for Hemophilia/Blood Factor Products require a prior authorization and will be screened for medical necessity and appropriateness
More informationFuture prospects for the treatment of haemophilia
Future prospects for the treatment of haemophilia Paul Giangrande Green Templeton College University of Oxford paul.giangrande@gtc.ox.ac.uk Topics to be covered: Extended half-life FVIII & IX products
More informationCORPORATE PRESENTATION January 2019
CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hemlibra (emicizumab-kxwh) Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hemlibra (emicizumab-kxwh) Prime Therapeutics will review Prior Authorization
More informationTopics Covered. FDA s Role in Expediting the Development of Novel Medical Products. How a Regulatory Agency Comes into Existence 3/5/2018
FDA s Role in Expediting the Development of Novel Medical Products Peter Marks, M.D., Ph.D. Director Center for Biologics Evaluation and Research Topics Covered Brief history of FDA Expediting product
More informationCorporate Presentation. Leader in AAV Gene Therapy
Corporate Presentation Leader in AAV Gene Therapy January 4, 2019 Forward-looking statements This presentation includes forward-looking statements, within the meaning of Section 27A of the Securities Act
More informationFourth Quarter and Full Year Financial and Operational Results Conference Call March 21, 2018
Fourth Quarter and Full Year 2017 Financial and Operational Results Conference Call March 21, 2018 Copyright Akari Therapeutics, Plc - 2018 Disclaimers Certain statements in this presentation constitute
More information37 th Annual J.P. Morgan Healthcare Conference
37 th Annual J.P. Morgan Healthcare Conference January 2019 T H E R A P E U T I C S Courageous Patients. Bold Effort. Safe Harbor Except for statements of historical fact, any information contained in
More informationJ.P. Morgan 36 th Annual Healthcare Conference. January 10, 2018
J.P. Morgan 36 th Annual Healthcare Conference January 10, 2018 Forward Looking Statements BioCryst s presentation may contain forward looking statements, including statements regarding future results,
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX. Updated July 2017
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Updated July 2017 Safe Harbor Statement This presentation (the Presentation ) includes forward looking statements within the meaning of the Private Securities Litigation
More informationVisionary Science for Life Changing Cures 2018
Visionary Science for Life Changing Cures 2018 1 Forward Looking Statements Today s presentation includes forward-looking statements intended to qualify for the Safe Harbor from liability established by
More informationTarget Selection in the area of Gene Therapy Harald Petry, PhD
Target Selection in the area of Gene Therapy Harald Petry, PhD Chief Scientific Officer Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and
More informationCatalyst Biosciences. Essential Medicines for Hemophilia Greater Convenience Superior Outcomes. 21 June 2018
Catalyst Biosciences Essential Medicines for Hemophilia Greater Convenience Superior Outcomes 21 June 2018 Forward looking statements This presentation includes forward-looking statements that involve
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationStifel Nicolaus Healthcare Conference. September 2012
Stifel Nicolaus Healthcare Conference September 212 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of
More informationCNS Gene Regulation Platform
CNS Gene Regulation Platform 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationRegulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling
Presentation title Date 1 Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling Marianne Bork Samuelsen, Msc Pharm Regulatory Affairs Novo Nordisk
More informationImmuno-Oncology Program
Immuno-Oncology Program 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
More informationConference call transcript for the March 2017 Quarterly Report
ASX ANNOUNCEMENT Conference call transcript for the March 2017 Quarterly Report Sydney Australia, 31 May 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript
More informationCorporate Presentation. June 2015
Corporate Presentation June 2015 Forward Looking Statement/Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions.
More informationCatabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress
Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress -- MoveDMD Trial Data Through One Year of Treatment Reinforce Edasalonexent Potential as Disease-Modifying
More informationSanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care
Sanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care January 22, 2018 Forward Looking Statements This presentation contains forward-looking statements.
More informationpsivida Transforms into Commercial Stage Specialty BioPharmaceutical Company ASCRS April 12, 2018 NASDAQ: EYPT
psivida Transforms into Commercial Stage Specialty BioPharmaceutical Company OIS @ ASCRS April 12, 2018 NASDAQ: EYPT Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
More informationA Patient-Centered Approach to Understanding the Burden of Inhibitors
A Patient-Centered Approach to Understanding the Burden of Inhibitors Mark W. Skinner, JD FDA-CERSI Collaborative Workshop on Predictive Immunogenicity for Better Clinical Outcomes 3-4 Oct 2018 Washington,
More informationAffigenix Biosolutions Private Ltd, 265/ 1F, KSSIDC Industrial Area Bangalore, Karnataka,India
Host Cell Protein & Other Impurity Clearance Assays for Biosimilar Development Omics Biowaivers, Biologics & Biosimilars- Oct 29, 2014 Affigenix Biosolutions Private Ltd, 265/ 1F, KSSIDC Industrial Area
More informationResults to be Presented at LDN WORLD Symposium in February Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13
Amicus Therapeutics Announces Positive Results from All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease Strong Proof-of-Concept Data for Chaperone
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationAdvancing Mitochondrial Medicine. Günther Metz, SVP Business Development
Advancing Mitochondrial Medicine Günther Metz, SVP Business Development Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to
More informationARTICLE DISCUSSION: MARCH 2018 IRB MEMBER TRAINING
ARTICLE DISCUSSION: SEVERE TOXICITY IN NONHUMAN PRIMATES AND PIGLETS FOLLOWING HIGH- DOSE INTRAVENOUS ADMINISTRATION OF AN ADENO-ASSOCIATED VIRUS VECTOR EXPRESSING HUMAN SMN MARCH 2018 IRB MEMBER TRAINING
More informationDivision of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
Reference No.: FDAA10017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 VIA WEB SUBJECT: Approval Pathway for Biosimilar and Interchangeable
More information80% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001)
March 2, 2016 BioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016 80% Reduction in Clinical Disease
More informationNASDAQ: EYES. Investor Presentation
Investor Presentation 2016 Forward Looking Statements This presentation contains certain forward looking information about Second Sight that is intended to be covered by the safe harbor for "forward looking
More informationFirst Quarter 2018 Financial Results. May 8, 2018
First Quarter 2018 Financial Results May 8, 2018 Agenda Introduction Sarah Carmody, Senior Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer First Quarter
More information2016 Glaukos Corporation. August 2016
August 2016 DISCLAIMER All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will
More informationCymaBay Therapeutics (CBAY)
Company Update CymaBay Therapeutics (CBAY) CymaBay Finds Success in Phase II Study for Seladelpar, Observed Drug Profile is Likely Competitive. On July 17 th, CymaBay Therapeutics (NasdaqCM: CBAY) announced
More informationvision is our mission
vision is our mission NASDAQ: OPHT March 2019 Forward-looking Statements Any statements in this presentation about Ophthotech s future expectations, plans and prospects constitute forward-looking statements
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationGene Therapy: Fellow s Conference Fred Hutchinson Cancer Research Center. Zandra K. Klippel
Gene Therapy: Did we finally get it right? Fellow s Conference Fred Hutchinson Cancer Research Center University it of Washington Zandra K. Klippel March 2012 Introduction >6000 human diseases are monogenic
More informationPTC Acquisition of Agilis Biotherapeutics
PTC Acquisition of Agilis Biotherapeutics July 19, 2018 1 Forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 All statements, other than those of historical
More informationOPT-302: A Novel Therapy for Eye Diseases
OPT-302: A Novel Therapy for Eye Diseases Corporate & Investor Presentation ASX Small & Mid-Cap Conference Sydney, September 6 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment in Opthea
More informationNew Approaches to Haemophilia. Edward G. Tuddenham
New Approaches to Haemophilia Edward G. Tuddenham Milestones in Haemophilia care 1950: Fresh frozen plasma; requiring hospitalisation and not very effective 1964: Judith Poole discovers a simple way to
More informationComparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017
Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical
More informationNASDAQ: ABEO
NASDAQ: ABEO www.abeonatherapeutics.com 1 Safe Harbor Statement This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933,
More informationRoche s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors
Media Release Basel, 26 June 2017 Roche s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful
More informationPre-existing anti-viral vector antibodies in gene therapy
Pre-existing anti-viral vector antibodies in gene therapy Impact on assays, study conduct and data interpretation Mark N Milton, Executive Director DMPK-Bx, Novartis AAPS NBC, May 2016 Gene Therapy Treatment
More informationthese bases in a specific sequence can change the structure and nature of the gene and is what is known as a gene mutation.
When I started at Medical School in 1974, the structure of DNA had only been identified some 21 years earlier in 1953 by Watson and Crick. During my undergraduate training, we only had one lecture on DNA
More information2017 Well Characterized Biological Products
2017 Well Characterized Biological Products Gene Therapy Treatments for Hemophilia A & B Process Validation Considerations in the Manufacturing of Gene Therapy Products Robert Baffi, Ph.D., MBA Executive
More informationGaining Momentum in Gene Therapy
Gaining Momentum in Gene Therapy Corporate Presentation September 2018 Forward-looking Statements Statements contained in this document regarding matters that are not historical facts are forward-looking
More informationCatalyst Biosciences
Catalyst Biosciences Essential Medicines for Hemophilia Greater Convenience Superior Outcomes 12 February 2018 Forward Looking Statements This presentation includes forward-looking statements that involve
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation
More informationDuchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Clinical and Commercial Strategy Dr. Leslie Hudson, President and CEO September 10, 2008 Duchenne Muscular Dystrophy (DMD) Defects in the dystrophin gene; no protein expression
More informationPTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders. March 2018
PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders March 2018 Mar-18 Page 1 Forward looking statements within the meaning of The Private Securities Litigation
More informationPTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders JANUARY 2018
PTC Therapeutics: 20 years of commitment to bringing new treatments to patients with rare disorders JANUARY 2018 Jan-18 Page 1 Forward looking statements within the meaning of The Private Securities Litigation
More informationtrial. Key trial data points:
February 23, 2015 ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference RAMSEY, N.J., Feb. 23, 2015
More information